First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation StudyAmit Khot, Simon J. Harrison, Kylee Maclachlan et al.|Cancer Discovery|2019Cited by 201
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trialBenjamin Diamond, Ola Landgren, Neha Korde et al.|The Lancet Haematology|2021Cited by 95